1890 results about "Linolenic acid" patented technology

The present invention relates to fatty acid desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to ETA; eicosapentaenoic acid (EPA) to docosapentaenoic acid (DPA); and arachidonic acid (ARA) to EPA. Nucleic acid sequences encoding codon-optimized desaturases and elongases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the codon-optimized desaturase or elongases, and recombinant host microorganisms expressing increased levels of desaturase or elongase are described.

The present invention relates to methods for the production of ω-3 and / or ω-6 fatty acids in oleaginous yeast. Thus, desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to arachidonic acid (ARA); ETA to eicosapentaenoic acid (EPA); DGLA to ETA; EPA to docosapentaenoic acid (DPA); and ARA to EPA have been introduced into the genome of Yarrowia for synthesis of ARA and EPA.

Lipo-chito oligosaccharides (LCOs) are produced by culturing rhizobacteria cells in or on a culture medium comprising at least one of: jasmonic acid or a derivative thereof; linoleic acid or a derivative thereof; or linolenic acid or a derivative thereof. Preferably, the rhizobacteria cells are Bradyrhizobium japonicum cells having the identifying characteristics of B. japonicum strain USDA 3. Preferably, the derivative of jasmonic acid is an ester thereof, preferably methyl jasmonate. Also provided are methods for improving LCO production at low temperatures, particularly temperatures below 25° C.

The present invention is directed to processes for preparing oil compositions having a high concentration of poly-unsaturated fatty acids and oil compositions having a low concentration of α-linolenic acid. In addition, the present invention is directed to processes for preparing oil compositions having advantageous stability characteristics.

This invention relates to compositions and methods for preventing and treating cognitive dysfunction or memory impairment. The compositions include an effective amount of citicoline, or pharmaceutically-acceptable salts thereof, and one or more of the compounds selected from the group consisting of linoleic acid and linolenic acid. Other compositions of this invention include an effective amount of citicoline, or pharmaceutically-acceptable salt thereof, wherein said citicoline is metabolized to form at least one of cytidine, uridine, and choline. Still other compositions of this invention include effective amounts of choline, cytidine, and / or uridine, or their pharmaceutically-acceptable salts. This invention also encompasses methods for preparing these compositions.

A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an lkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt. / wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt. / wt. % of the formulation. Preferably, the formulation is administered, in combination with a propellant, to the buccal cavity, using a metered dose dispenser.

The invention relates to edible nutritious oil which is characterized in that the contents of saturated fatty acid, oleic acid, linoleic acid and linolenic acid are respectively 8 to 16 percent, 42 to 56 percent, 13 to 23 percent and 13 to 30 percent of total fatty acid. With the proposal of eating less saturated fatty acid and linoleic acid and more oleic acid and linolenic acid from the international alimentology community, the edible oil is designed based on the particular reference that the ratio of the linoleic acid to the linolenic acid is close to 1 to 1 in the meal of human beings and people in Crete, Greece 100 years ago. The edible oil which has more balanced ratio between the fatty acid is quite suitable for human beings and has very important effects on reducing human beings fatness, hypertension, high blood fat, cardiovascular and cranial vascular diseases and cancers and reinforcing intelligence development. In addition, the edible oil has high quality and low price.

A nutrition bar comprising about 10% wt or more of soy and / or rice protein, at least one transition metal or transition metal compound, and about 2% wt or more of a humectant, and wherein the at least one transition metal or transition metal compound is in a substantially water insoluble form at 20° C. or the nutrition bar has an Aw of 0.45 or less or about 1% wt or more of the soy and / or rice protein is in the form of nuggets and the humectant is selected from polyols. The bars have elevated levels of soy and / or rice protein, yet do not suffer unacceptable from a deterioration in taste or other organoleptic properties over time. In other aspects, a nutrition bar or other food which incorporates pro-oxidants and / or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and / or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules / microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.

A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt. / wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt. / wt. % of the formulation. The propellant, e.g. a fluorocarbon propellant, provides enhanced absorption of the pharmaceutical agent.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to omega3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, omega6-docosapentaenoic acid or omega3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The present invention relates to fungal Δ-15 fatty acid desaturases that are able to catalyze the conversion of linoleic acid (18:2, LA) to alpha-linolenic acid (18:3, ALA). Nucleic acid sequences encoding the desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the desaturase genes, and recombinant host plants and microorganisms expressing increased levels of the desaturases are described. Methods of increasing production of specific omega-3 and omega-6 fatty acids by over-expression of the Δ-15 fatty acid desaturases are also described herein.

The present invention relates to methods for the production of ω-3 and / or ω-6 fatty acids in oleaginous yeast. Thus, desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to arachidonic acid (ARA); ETA to eicosapentaenoic acid (EPA); DGLA to ETA; EPA to docosapentaenoic acid (DPA); and ARA to EPA have been introduced into the genome of Yarrowia for synthesis of ARA and EPA.

The present invention is directed to seed oil compositions that can be used for cooking and frying applications. These oil compositions of the present invention have advantageous stability characteristics. In some embodiments, the oil compositions have a low concentration of α-linolenic acid.

Disclosed herein are alternative, enhanced, and cheaper methods of improving cognitive functions in a subject using a lipid composition conjugated with omega-3 and omega-6 fatty acids, with specific amounts and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and eicosapentaenoyl (EPA), e.g. utilizing different sources of lipids.Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease.The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

The present invention relates to fungal Δ-15 fatty acid desaturases that are able to catalyze the conversion of linoleic acid (18:2, LA) to alpha-linolenic acid (18:3, ALA). Nucleic acid sequences encoding the desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the desaturase genes, and recombinant host plants and microorganisms expressing increased levels of the desaturases are described. Methods of increasing production of specific omega-3 and omega-6 fatty acids by over-expression of the Δ-15 fatty acid desaturases are also described herein.

The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The invention discloses a method for extracting peony seed oil. In the method, peony seed powders are put in a supercritical CO2 extractor for supercritical extraction, and oil is collected to obtain the provided peony seed oil. In the method, the supercritical extraction temperature ranges from 30 to 50 DEG C, 45 DEG C is optimized, the pressure for supercritical extraction ranges from 20 to 35MPa, and 30MPa is optimized; time for supercritical extraction ranges from 0.5 to 2 hours, and 1 hour is optimized. The grain diameter of the peony seed powders ranges from 20 to 60 screen meshes. The provided supercritical CO2 extracting method for preparing peony seed oil needs no organic reagents, has simple and convenient extracting and separating method, the extraction yield can reach 27 percent, and obtained unsaturated fatty acid can reach 90 percent; and compared with the prior organic solvent extraction method, the contents of linolenic acid and linoleic acid in peony oil are increased to certain extent, and the extraction is completer.

This invention relates to a new elongase gene having the sequence SEQ ID NO: 1 or its derivatives, to a gene construct comprising this sequence or its derivatives and to its use. The inventive nucleic acid sequence encodes a polypeptide which elongates α-linolenic acid (C18:3 d9, 12, 15) by at least two carbon atoms whereas γ-linolenic acid (C18:3 d6, 9, 12) is not elongated. The invention additionally relates to vectors or organisms comprising an elongase gene having the sequence SEQ ID NO: 1 or its derivatives. The invention further relates to a process for the production of polyunsaturated fatty acids (=PUFAs) with an organism which comprises the elongase gene and which organism produces high amounts of oils and especially oils with a high content of unsaturated fatty acids. Additionally the invention relates to an oil and / or fatty acid composition with a higher content of polyunsaturated C20 or C22 fatty acids with at least two double bonds and / or to a triacylglycerol composition with a higher content of said polyunsaturated fatty acids.

Seeds, plants and oils are provided having high oleic acid; low linoleic acid; and low linoleic acid plus linolenic acid; and advantageous functional or nutritional properties. Plants are disclosed that contain a mutation in a delta-12 or delta-15 fatty acid desaturase gene. Preferred plants are rapeseed and sunflower plants. Plants carrying such mutant genes have altered fatty acid composition in seeds. In one embodiment, a plant contains a mutation in a region having the conserved motif His-Xaa-Xaa-Xaa-His, found in delta-12 and delta-15 fatty acid desaturases. A preferred motif has the sequence His-Glu-Cys-Gly-His. A preferred mutation in this motif has the amino acid sequence His-Lys-Cys-Gly-His. Nucleic acid fragments are disclosed that comprise a mutant delta-12 or delta-15 fatty acid desaturase gene sequence.

The invention discloses a preparation method of grease with a humanized structure. The preparation method comprises the following steps: carrying out intra-molecular rearrangement reaction to palm oil with palmitic acid content of higher than 50% under the action of catalyst to obtain Sn-2 locus triglyceride with palmitic acid content of higher than 50%; and carrying out ester exchange reaction to the Sn-2 locus triglyceride with palmitic acid content of higher than 50% with mixed fatty acid or non-glyceride under the action of 1,3 locus Specificity lipase, and then subjecting the reaction product to after treatment, so as to obtain the grease with humanized structure, wherein the mixed fatty acid is mixture of at least two selected from the group consisting of decanoic acid, lauric acid,myristic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid and linolenic acid. The vegetable oils are used as the raw material according to the method, so the safety is high; the preparation process is simple, the reaction time is short, the enzyme dosage is low, and the cost is low; and the prepared grease with the humanized structure is very similar to the beast milk fat in the composition of fatty acid and the structural distribution of triglyceride, so the grease can be added in infant formula or formula foods and used as breast milk fat substitute.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogama linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachiodonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The invention discloses functional fatty powder and a preparation method thereof, and belongs to the technical field of feeds. The functional fatty powder is characterized in that raw materials comprise the following components in parts by weight: 30-50 parts of concentrated omega-fatty acid fat, 10-20 parts of lecithin, 8-15 parts of concentrated linolenic acid fat, 8-15 parts of MCT, 1-5 parts of choline, 1.5-5.5 parts of nicotinamide, 1-5 parts of a composite emulsifying agent, 3-8 parts of a composite antioxidant, 2-8 parts of vitamin C, and 40-70 parts of encrusting substances or 30-60 parts of carriers. The functional fatty powder provided by the invention is small in addition quantity, high in cost performance ratio, good in stability, high in nutrient value and high in fat utilization rate; the functional fatty powder not only can greatly improve the growing property and the reproductive property of animals but also can improve the immunity of the animals and promote the development of animal organisms, so that the functional fatty powder is an excellent feed additive.

This disclosure concerns a plant of the genus, Brassica, or parts thereof, which comprise one or more traits selected from the group consisting of high oleic acid content, low linolenic acid content, increased herbicide resistance, restorer of cytoplasmic male sterility, and increased clubroot disease (Plasmodiophora brassicae) resistance, compared to a wild-type plant of the same species. This disclosure further relates to wild-type and mutant alleles of genes involved in these traits, molecular markers linked thereto, and methods of their use.

The blended vegetable oil with balanced nutrients is compounded with three kinds of vegetable oil in different characteristics. The three kinds of vegetable oil include oleic acid type vegetable oil with high unsaturated fatty acid content, linoleic acid type vegetable oil with high N-6 polyunsaturated fatty acid content, and linolenic acid type vegetable oil with high N-3 polyunsaturated fatty acid content. The blended vegetable oil with balanced nutrients has balanced contents of oleic acid, linoleic acid and linolenic acid, can meet the physiological requirement of human body, and has the advantages of wide material source, low cost, rich nutrients, etc.

Seeds, plants and oils are provided having high oleic acid; low linoleic acid; and low linoleic acid plus linolenic acid; and advantageous functional or nutritional properties. Plants are disclosed that contain a mutation in a delta-12 or delta-15 fatty acid desaturase gene. Preferred plants are rapeseed and sunflower plants. Plants carrying such mutant genes have altered fatty acid composition in seeds. In one embodiment, a plant contains a mutation in a region having the conserved motif His-Xaa-Xaa-Xaa-His, found in delta-12 and delta-15 fatty acid desaturases. A preferred motif has the sequence His-Glu-Cys-Gly-His. A preferred mutation in this motif has the amino acid sequence His-Lys-Cys-Gly-His. Nucleic acid fragments are disclosed that comprise a mutant delta-12 or delta-15 fatty acid desaturase gene sequence.